Pharmacological implications of MMP-9 inhibition by ACE inhibitors.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Medicinal Chemistry

• Publication date

  2009-03-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986709787846514PMID 19355890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.

  2008cited by this paper
• Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.

  2008cited by this paper
• Inhibitory profiles of captopril on matrix metalloproteinase-9 activity.

  2008cited by this paper
• Involvement of integrins, MAPK, and NF-kappaB in regulation of the shear stress-induced MMP-9 expression in endothelial cells.

  2007cited by this paper
• ACE inhibitors to block MMP-9 activity: new functions for old inhibitors.

  2007cited by this paper
• Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity.

  2007cited by this paper
• Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters.

  2007cited by this paper
• Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site.

  2007cited by this paper
• Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

  2007cited by this paper
• Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.

  2007cited by this paper
• Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9.

  2007cited by this paper
• Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction.

  2006cited by this paper
• Do metalloproteinases destabilize vulnerable atherosclerotic plaques?

  2006cited by this paper
• Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture.

  2006cited by this paper
• Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.

  2006cited by this paper
• Angiotensin receptor blockers do not increase risk of myocardial infarction.

  2006cited by this paper
• Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox

  2006cited by this paper
• The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet

  2005cited by this paper
• Pathophysiology of Coronary Artery Disease

  2005cited by this paper
• Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction.

  2005cited by this paper
• Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

  2005cited by this paper
• Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations

  2005cited by this paper
• Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

  2004cited by this paper
• Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2–Dependent Matrix Metalloproteinase Activity

  2004cited by this paper
• Angiotensin receptor blockers and myocardial infarction

  2004cited by this paper
• Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.

  2004cited by this paper
• Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.

  2004cited by this paper
• Chymase as a novel target for the prevention of vascular diseases.

  2004cited by this paper
• Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet

  2003cited by this paper
• Crystal structure of Drosophila angiotensin I‐converting enzyme bound to captopril and lisinopril 1

  2003cited by this paper
• Crystal structure of the human angiotensin-converting enzyme–lisinopril complex

  2003cited by this paper
• Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase.

  2002cited by this paper
• Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.

  2002cited by this paper
• Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP

  2002cited by this paper
• Selective Matrix Metalloproteinase Inhibition Reduces Left Ventricular Remodeling but Does Not Inhibit Angiogenesis After Myocardial Infarction

  2002cited by this paper
• Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.

  2002cited by this paper
• Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.

  2001cited by this paper
• Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE)

  2001cited by this paper
• Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.

  2000cited by this paper
• Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery.

  2000cited by this paper
• Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.

  2000cited by this paper
• Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

  2000cited by this paper
• Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress.

  2000cited by this paper
• Anti‐atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high‐cholesterol diet

  1999cited by this paper
• Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.

  1998cited by this paper
• Enhanced expression of angiotensin‐converting enzyme is associated with progression of coronary atherosclerosis in humans

  1997cited by this paper
• Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis.

  1997cited by this paper
• Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.

  1997cited by this paper
• Dog Mast Cell α-Chymase Activates Progelatinase B by Cleaving the Phe88-Gln89 and Phe91-Glu92 Bonds of the Catalytic Domain*

  1997cited by this paper
• Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.

  1994cited by this paper
• Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases.

  1993cited by this paper
• Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties.

  1992cited by this paper

• Mild therapeutic hypothermia protects against inflammatory and proapoptotic processes in the rat model of cochlear implant trauma.

  2022cites this paper
• Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors.

  2022cites this paper
• Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications

  2021cites this paper
• Potential New Treatments for Kawasaki Disease, Its Variations, and Multisystem Inflammatory Syndrome

  2021cites this paper
• Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials

  2020cites this paper
• Renin-angiotensin system activation and imbalance of matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 in cold-induced stroke.

  2019cites this paper
• [Markers of Vascular Wall Fibrosis Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Ischemic Heart Disease with and without Concomitant Type-2 Diabetes Mellitus].

  2019cites this paper
• Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

  2019cites this paper
• Matrix Metalloproteinase-9-Dependent Mechanisms of Reduced Contractility and Increased Stiffness in the Aging Heart

  2018cites this paper
• Rice bran protein hydrolysates reduce arterial stiffening, vascular remodeling and oxidative stress in rats fed a high-carbohydrate and high-fat diet

  2018cites this paper
• Design, Synthesis, and Pharmacological Activity of a New Matrix Metalloproteinase-9 Inhibitor

  2018cites this paper
• The impact of aging on cardiac extracellular matrix

  2017cites this paper
• Matrix metalloproteinase‐9‐dependent mechanisms of reduced contractility and increased stiffness in the aging heart

  2016cites this paper
• Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.

  2016cites this paper
• Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease)

  2015cites this paper
• Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury

  2015cites this paper
• GnRH-(1-5) activates matrix metallopeptidase-9 to release epidermal growth factor and promote cellular invasion.

  2015cites this paper
• Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury

  2015cites this paper
• Significance of matrix metalloproteinase-9 inhibition by imidapril for prevention of abdominal aortic aneurysms in angiotensin II type 1 receptor-knockout mice.

  2013cites this paper
• Matrix metalloproteinases: drug targets for myocardial infarction.

  2013cites this paper
• Myofibroblasts, regeneration or renal fibrosis--is there a decisive hint?

  2013cites this paper
• Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes.

  2012cites this paper
• Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension

  2012cites this paper
• A Comparison Between Imidapril and Ramipril on Attenuation of Ventricular Remodeling After Myocardial Infarction

  2012influential citation
• Matrix metalloproteinase‐2 inhibition by temocapril and its important role in peritoneal transport

  2012cites this paper
• Imidapril inhibits cerebral aneurysm formation in an angiotensin-converting enzyme-independent and matrix metalloproteinase-9-dependent manner.

  2012cites this paper
• An Emerging Role of Degrading Proteinases in Hypertension and the Metabolic Syndrome: Autodigestion and Receptor Cleavage

  2012cites this paper
• Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase‐9 expression via a protein kinase Cδ/p38/extracellular signal‐regulated kinase pathway in phorbol myristate acetate‐induced THP‐1 macrophages

  2011cites this paper
• Acute myocardial infarction is reflected in salivary matrix metalloproteinase-8 activation level.

  2011cites this paper
• MMPs are regulatory enzymes in pathways of inflammatory disorders , tissue injury , malignancies and remodelling of the lung

  2011cites this paper
• MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung

  2011cites this paper
• Metalloproteinase Inhibitors: Status and Scope from Marine Organisms

  2010cites this paper
• Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.

  2010cites this paper